Showing results (131-140 of 259) with videos related to
Sort By:
Pageof 26
Chest|January 28, 2019
A Novel Algorithm to Analyze Epidemiology and Outcomes of Carbapenem Resistance Among Patients With Hospital-Acquired and Ventilator-Associated Pneumonia: A Retrospective Cohort StudyMarya D Zilberberg, Brian H Nathanson, Kate Sulham, et al.Journal of Critical Care|December 6, 2011
The adequacy of timely empiric antibiotic therapy for ventilator-associated pneumonia: an important determinant of outcomeJohn G Muscedere, Andrew F Shorr, Xuran Jiang, et al.Archives of Internal Medicine|September 30, 2009
Mortality and need for mechanical ventilation in acute exacerbations of chronic obstructive pulmonary disease: development and validation of a simple risk scoreYing P Tabak, Xiaowu Sun, Richard S Johannes, et al.Medicine|March 9, 2017
Recurrent Clostridium difficile infection among Medicare patients in nursing homes: A population-based cohort studyMarya D Zilberberg, Andrew F Shorr, William M Jesdale, et al.Surgical Infections|December 11, 2012
Risk factors for mixed complicated skin and skin structure infections to help tailor appropriate empiric therapyMarya Zilberberg, Scott T Micek, Marin H Kollef, et al.BMC Infectious Diseases|April 19, 2017
Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsisMarya D Zilberberg, Brian H Nathanson, Kate Sulham, et al.Critical Care (London, England)|July 16, 2016
Multidrug resistance, inappropriate empiric therapy, and hospital mortality in Acinetobacter baumannii pneumonia and sepsisMarya D Zilberberg, Brian H Nathanson, Kate Sulham, et al.Critical Care Medicine|July 25, 2012
Longitudinal changes in procalcitonin in a heterogeneous group of critically ill patientsSteven C Reynolds, Andrew F Shorr, John Muscedere, et al.Diagnostic Microbiology and Infectious Disease|January 30, 2013
Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trialsAndrew F Shorr, Marin Kollef, Paul B Eckburg, et al.Antimicrobial Resistance and Infection Control|December 12, 2017
30-day readmission, antibiotics costs and costs of delay to adequate treatment of Enterobacteriaceae UTI, pneumonia, and sepsis: a retrospective cohort studyMarya D Zilberberg, Brian H Nathanson, Kate Sulham, et al.Pageof 26